BR112013001879A2 - "método para aprefeiçoar o efeito de tratamento em um paciente que sofre de câncer gástrico, método in vitro, kit, uso de um olignucleotídeo ou polipetídio e uso de bevacizumabe" - Google Patents
"método para aprefeiçoar o efeito de tratamento em um paciente que sofre de câncer gástrico, método in vitro, kit, uso de um olignucleotídeo ou polipetídio e uso de bevacizumabe"Info
- Publication number
- BR112013001879A2 BR112013001879A2 BR112013001879A BR112013001879A BR112013001879A2 BR 112013001879 A2 BR112013001879 A2 BR 112013001879A2 BR 112013001879 A BR112013001879 A BR 112013001879A BR 112013001879 A BR112013001879 A BR 112013001879A BR 112013001879 A2 BR112013001879 A2 BR 112013001879A2
- Authority
- BR
- Brazil
- Prior art keywords
- gastric cancer
- bevacizumab
- treatment effect
- kit
- improving
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
Abstract
"método para aperfeiçoar o efeito de tratamento em um paciente que sofre de câncer gástrico, método in vitro, kit, uso de um oligonucleotídeo ou polipeptídio e uso de bevacizumabe" trata-se de métodos para aperfeiçoar o efeito de tratamento em um paciente que sofre de câncer gástrico, em particular, adenocarcinoma do estômago ou da junção gastroesofagiana ("gej"), pelo tratamento com bevacizumabe (avastin®) em combinação com um regime de quimioterapia pela determinação do nível de expressão de neuropilina em relação a um nível de controle determinado em pacientes que sofrem de câncer gástrico, em particular, adenocarcinoma do estômago ou da junção gastroesofagiana ("gej"). o efeito de tratamento aperfeiçoado pode ser sobrevivência geral aperfeiçoada ou sobrevivência livre de progressão aperfeiçoada. a presente invenção fornece adicionalmente métodos para avaliar a sensibilidade ou a responsividade de um paciente ao bevacizumabe (avastin®) em combinação com um regime de quimioterapia, pela determinação do nível de expressão da neuropilina em relação a um nível de controle determinado em pacientes que sofrem de câncer gástrico, em particular, adenocarcinoma do estômago ou da junção gastroesofagiana ("gej").
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10172812 | 2010-08-13 | ||
PCT/EP2011/063932 WO2012020123A2 (en) | 2010-08-13 | 2011-08-12 | Neuropilin as a biomarker for bevacizumab combination therapies |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013001879A2 true BR112013001879A2 (pt) | 2019-09-03 |
Family
ID=44543220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013001879A BR112013001879A2 (pt) | 2010-08-13 | 2011-08-12 | "método para aprefeiçoar o efeito de tratamento em um paciente que sofre de câncer gástrico, método in vitro, kit, uso de um olignucleotídeo ou polipetídio e uso de bevacizumabe" |
Country Status (12)
Country | Link |
---|---|
US (3) | US20130171134A1 (pt) |
EP (1) | EP2603239A2 (pt) |
JP (1) | JP2013539460A (pt) |
KR (1) | KR20140003393A (pt) |
CN (1) | CN103052404A (pt) |
AU (1) | AU2011288354A1 (pt) |
BR (1) | BR112013001879A2 (pt) |
CA (1) | CA2806447A1 (pt) |
MX (1) | MX2013001523A (pt) |
RU (1) | RU2013110780A (pt) |
SG (1) | SG187109A1 (pt) |
WO (1) | WO2012020123A2 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX366890B (es) | 2009-10-23 | 2019-07-30 | Millennium Pharm Inc | Moléculas de anticuerpo anti - gcc y composiciones y métodos relacionados. |
PT2841575T (pt) * | 2012-04-27 | 2019-10-11 | Millennium Pharm Inc | Moléculas de anticorpo anti-gcc e utilização das mesmas para testar a suscetibilidade à terapia direcionada a gcc |
WO2016115149A1 (en) * | 2015-01-12 | 2016-07-21 | Aveo Pharmaceuticals, Inc. | Neuropilin-1 as a serum based biomarker |
WO2021076852A1 (en) * | 2019-10-17 | 2021-04-22 | Board Of Regents, The University Of Texas System | Small extracellular vesicle-associated vegf as a predictor for therapeutic responses |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2109686A2 (en) * | 2007-01-18 | 2009-10-21 | University Of Southern California | Genetic markers for predicting responsiveness to combination therapy |
KR101179843B1 (ko) * | 2009-04-08 | 2012-09-04 | 경북대학교 산학협력단 | 뉴로필린 2의 위암 진단 및 치료용 용도 |
BR112012016229A2 (pt) * | 2010-01-19 | 2017-03-07 | Hoffmann La Roche | método para melhorar a sobrevida livre de progressão, método in vitro, kit, uso de um oligonucleotídeo ou polipetídeo e uso de bevacizumab |
-
2011
- 2011-08-12 AU AU2011288354A patent/AU2011288354A1/en not_active Abandoned
- 2011-08-12 SG SG2013003686A patent/SG187109A1/en unknown
- 2011-08-12 BR BR112013001879A patent/BR112013001879A2/pt not_active Application Discontinuation
- 2011-08-12 EP EP11751572.6A patent/EP2603239A2/en not_active Withdrawn
- 2011-08-12 RU RU2013110780/10A patent/RU2013110780A/ru unknown
- 2011-08-12 KR KR1020137006254A patent/KR20140003393A/ko not_active Application Discontinuation
- 2011-08-12 MX MX2013001523A patent/MX2013001523A/es unknown
- 2011-08-12 CN CN2011800383111A patent/CN103052404A/zh active Pending
- 2011-08-12 JP JP2013523635A patent/JP2013539460A/ja not_active Withdrawn
- 2011-08-12 CA CA2806447A patent/CA2806447A1/en not_active Abandoned
- 2011-08-12 WO PCT/EP2011/063932 patent/WO2012020123A2/en active Application Filing
-
2013
- 2013-01-09 US US13/737,586 patent/US20130171134A1/en not_active Abandoned
- 2013-03-13 US US13/802,003 patent/US20130183304A1/en not_active Abandoned
- 2013-03-13 US US13/802,205 patent/US20130177554A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2806447A1 (en) | 2012-02-16 |
CN103052404A (zh) | 2013-04-17 |
KR20140003393A (ko) | 2014-01-09 |
MX2013001523A (es) | 2013-02-27 |
WO2012020123A9 (en) | 2012-06-07 |
RU2013110780A (ru) | 2014-09-20 |
EP2603239A2 (en) | 2013-06-19 |
US20130171134A1 (en) | 2013-07-04 |
US20130177554A1 (en) | 2013-07-11 |
SG187109A1 (en) | 2013-03-28 |
WO2012020123A3 (en) | 2012-04-12 |
JP2013539460A (ja) | 2013-10-24 |
AU2011288354A1 (en) | 2013-01-24 |
US20130183304A1 (en) | 2013-07-18 |
WO2012020123A2 (en) | 2012-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bian et al. | Up-regulation of fatty acid synthase induced by EGFR/ERK activation promotes tumor growth in pancreatic cancer | |
Pan et al. | Tea polyphenol (−)-epigallocatechin 3-gallate suppresses heregulin-β1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling | |
EA201500219A1 (ru) | Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo | |
BRPI1007321A2 (pt) | métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo. | |
MY172580A (en) | Tumor tissue based biomarkers for bevacizumab combination therapies | |
WO2010059969A8 (en) | Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer | |
Kim et al. | Geographic differences in approach to advanced gastric cancer: Is there a standard approach? | |
PH12016501728A1 (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
BRPI0818318B8 (pt) | composição imunoestimuladora ativa, seus usos, vacina, uso de pelo menos cinco rnas isolados, e kit | |
Bian et al. | Elevated Rictor expression is associated with tumor progression and poor prognosis in patients with gastric cancer | |
BRPI0906435B8 (pt) | Anticorpo anti-cd79b quimérico, composto conjugado, formulação farmacêutica, método para determinar a presença da proteína cd79b, ensaio para detectar células de câncer, método para inibir proliferação celular, usos de um anticorpo, de um composto conjugado e de uma formulação farmacêutica, e método para a fabricação de um composto conjugado | |
NO20084546L (no) | Diagnostikk og behandlinger for tumorer | |
BR112013018399A2 (pt) | anticorpos anti-il1rap e seus usos para tratamento humano | |
BRPI0922350A2 (pt) | anticorpo humano, mólecula biespecífica,vetor de expressão, célula hospedeira eucariótica ou procariótoca recombinante, composição farmacêutica, uso do anticorpo ou da molécula biespecífica, métodos para inibir o desenvolvimento e/ou proliferação de uma célula tumoral que expressa o fator de tecido, para produzir um anticorpo, e para detectar a presença de fator de tecido em uma amostra, composição de diagnóstico, e, kit para detectar a presença de fator de tecido em uma amostra. | |
EA201100779A1 (ru) | Композиции антител к cxcr1 и способы их применения | |
BR112016002000A2 (pt) | Diagnóstico e terapia de câncer envolvendo células-tronco tumorais | |
MX343801B (es) | Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama. | |
NZ602840A (en) | Immuno-pet imaging of antibodies and immunoconjugates and uses therefor | |
EP2068929A4 (en) | METHOD OF DETECTING AND TREATING SKIN DISORDERS | |
MX339427B (es) | Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer pancreatico. | |
BR112013001879A2 (pt) | "método para aprefeiçoar o efeito de tratamento em um paciente que sofre de câncer gástrico, método in vitro, kit, uso de um olignucleotídeo ou polipetídio e uso de bevacizumabe" | |
HK1149956A1 (en) | Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex | |
AR089067A1 (es) | Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mama | |
BR112013014195A2 (pt) | Método para a identificação de um paciente, composição, uso de bevacizumabe para a preparação de uma composição farmacêutica, método para o tratamento de um distúrbio proliferativo e composição, uso ou método | |
AR084163A1 (es) | Metodo para el diagnostico de un carcinoma y usos del mismo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |